Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Travere Therapeutics reported strong growth for 2025 driven by its kidney drug FILSPARI. Fourth-quarter U.S. net product sales were $126.6 million, up from $73.5 million a year earlier, with FILSPARI contributing $103.3 million, a 108% increase. Full-year U.S. net product sales reached $410.5 million, compared with $226.7 million in 2024, including FILSPARI net product sales of $322.0 million, up 144%.
GAAP net income for Q4 2025 was $2.7 million, versus a loss of $60.3 million in Q4 2024, while full-year GAAP net loss narrowed to $25.5 million from $321.5 million. On a non-GAAP basis, the company reported Q4 net income of $33.3 million and full-year 2025 net income of $81.1 million.
Cash, cash equivalents and marketable securities totaled $322.8 million as of December 31, 2025, and Travere expects a $25 million sales-based milestone from Mirum in the first half of 2026. The FDA is reviewing a supplemental application for FILSPARI in FSGS with a PDUFA target action date of April 13, 2026. Enrollment has resumed in the Phase 3 HARMONY trial of pegtibatinase for classical homocystinuria.
Armistice Capital, LLC and Steven Boyd filed Amendment No. 8 to a Schedule 13G/A reporting beneficial ownership of 3,763,891 shares of Travere Therapeutics, Inc.
The filing states this equals 4.21% of the class and shows shared voting and shared dispositive power over 3,763,891 shares as of 12/31/2025. The filing is a joint reporting statement by Armistice Capital (investment manager to the Master Fund) and Steven Boyd, dated 02/17/2026.
Elizabeth Reed has filed a notice of intent to sell 10,000 shares of TVTX common stock. The planned sale is to be executed through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of February 17, 2026, and an aggregate market value of $278,317.
The 10,000 shares to be sold were acquired the same day through a stock option exercise from the issuer, paid in cash. Over the prior three months, Reed also sold TVTX common shares on several dates, generating gross proceeds ranging from $96,360.09 to $273,420.00 per transaction.
Perceptive Advisors LLC and affiliated entities report a significant minority stake in Travere Therapeutics, Inc. They beneficially own 4,278,180 shares of common stock, representing 4.8% of the company’s outstanding shares, based on 89,472,327 shares outstanding as of October 27, 2025.
The shares are directly held by Perceptive Life Sciences Master Fund, Ltd., with voting and investment power shared among the Master Fund, Perceptive Advisors, and Joseph Edelman. The group certifies the investment was not made to change or influence control of Travere Therapeutics.
Travere Therapeutics Inc. received an amended Schedule 13G/A from Macquarie entities indicating they no longer hold a reportable stake in the company’s common shares. Macquarie Group Limited, Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust each report beneficial ownership of 0 shares, or 0.00% of the class, as of 12/31/2025.
The filers state the securities referenced were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Travere Therapeutics.
Travere Therapeutics Inc received a major shareholder disclosure from State Street Corporation, which reported beneficial ownership of 4,756,666 Travere common shares, representing 5.3% of the class as of December 31, 2025.
State Street reports shared voting power over 4,485,757 shares and shared dispositive power over 4,756,666 shares, with no sole voting or dispositive authority. The position is certified as held in the ordinary course of business and not for changing or influencing control of Travere.
Travere Therapeutics, Inc. Chief Medical Officer Jula Inrig reported planned sales of company stock. On February 4, 2026, Inrig sold 1,547 Travere common shares at a weighted average price of $32.11 and an additional 232 shares at a weighted average price of $32.85.
These transactions were made under a written trading plan adopted on May 28, 2025 that meets Rule 10b5-1(c) requirements and include shares sold to cover tax obligations from vesting restricted stock units. Following these sales, Inrig directly held 105,706 Travere common shares.
Travere Therapeutics, Inc. chief financial officer Christopher R. Cline reported two open‑market sales of company common stock on February 4, 2026. He sold 1,635 shares at a weighted average price of $32.14 and 110 shares at $32.90, and continued to hold 111,226 shares directly afterward.
According to the filing, these transactions were executed under a pre‑established Rule 10b5‑1 trading plan adopted on May 28, 2025, and include sales to cover tax obligations arising from the vesting of restricted stock units.
Travere Therapeutics Chief Legal Officer Elizabeth E. Reed reported planned stock sales under a Rule 10b5-1 trading plan. On February 4, 2026, she sold 2,485 shares of common stock at a weighted average price of $32.07 and 509 shares at a weighted average price of $32.74.
The filing notes that the plan was adopted on June 16, 2025 and that the transactions include shares sold to cover tax obligations from vesting restricted stock units. After these sales, Reed directly owned 105,211 shares of Travere Therapeutics common stock.
Elizabeth Reed filed a Rule 144 notice to sell 2,994 shares of common stock through Morgan Stanley Smith Barney LLC on or about 02/04/2026 on NASDAQ, with an aggregate market value of 96,360.09.
The filing also lists prior sales during the past three months: 7,175 shares of common stock sold on 02/03/2026 for gross proceeds of 230,463.88, and 10,000 shares sold on 01/20/2026 for gross proceeds of 273,420.00.